COVID-19, rheumatic diseases and immune dysregulation—a perspective

Tariq, Shahna; Eeden, Charmaine van; Tervaert, Jan Willem Cohen; Osman, Mohammed

doi:10.1007/s10067-020-05529-y

Cited by 14 publications

(12 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The underlying immune dysregulation in various autoimmune rheumatic diseases (AIRD) is a potential risk for prolonged viremia and severe novel coronavirus disease 2019 (COVID-19) [ 1 ]. Thus, they may be at higher risk of COVID-19 [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Cherian¹,

Paul²,

Ahmed

et al. 2021

Rheumatol Int

View full text Add to dashboard Cite

Patients with rheumatic and musculoskeletal (RMD) diseases may be at higher risks for COVID-19 infection. Data on the safety of the adenoviral vector-borne ChAdOx1 nCoV-19 and the heat-inactivated BBV152 Vaccines in this group are limited. 724 patients with RMD who had received at least one dose of either the ChAdOx1 or the BBV152 were audited to find out post-vaccination adverse effect (AE) or disease flares. The AE rates in patients with autoimmune rheumatic disease (AIRD) were compared with those with non-AIRD RMDs. The mean age of the cohort was 59.9 (± 10.43) years with a female ( n = 581; 80.24%) majority. 523 (70.8%) had AIRD. The ChAdOx1 and the BBV152 vaccines were received by 624 (86.18%) and 77 (10.63%), respectively. 23 (3.17%) were unaware of which vaccine they had received. 238 (32.87%) of patients had at least one comorbidity. 436 (60.22%) participants [306 (59.64%) of those with AIRD and 130 (61.61%) with other RMDs] had at least one adverse effect (AE). Four patients reported flare of arthritis that resolved within 5 days. No patient had any severe AE or required hospitalization. All AEs were self-limiting. Both the ChAdOx1 and the BBV152 vaccines appear safe in RMDs. AEs do not differ between patients with AIRD or non-AIRD. This information can help negate vaccine hesitancy amongst all stakeholders. Supplementary Information The online version contains supplementary material available at 10.1007/s00296-021-04917-0.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Cherian¹,

Paul²,

Ahmed

et al. 2021

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…During the COVID-19 outbreak, the prevalence of dermatomyositis was witnessed surge in India ( 26 ). Regarding the inconsistent prevalence of COVID-19 among distinct RADs, a study speculated that for certain RADs, the activity of underlying immune pathways were not completely the same ( 27 ), which results in the diverse involvement of RAD in the pathogenesis. Besides, this trend is also associated with the incidence of specific RADs themselves, thus it cannot be concluded that the prevalence of these diseases in COVID-19 is elevated.…”

Section: Epidemiological Featuresmentioning

confidence: 99%

Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review

2021

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) has been in pandemic for more than 1 year, with serious negative effects produced worldwide. During this period, there have been a lot of studies on rheumatic autoimmune diseases (RADs) combined with COVID-19. The purpose of this study is to review and summarize these experiences. Pubmed, Web of science, Embase and the Cochrane library were searched from January 15, 2020 to July 15, 2021 using RADs and COVID-19 related keywords. Based on a comprehensive review of studies covering 16 countries, the prevalence of COVID-19 does not necessarily increase in RADs patients compared to the general population. In RADs population infected with COVID-19, a high proportion of female patients (54.44~95.2%), elderly patients (≥50y, 48~75.88%), and patients with pre-existing comorbidities (respiratory, 4.8~60.4%; endocrine, 8.52~44.72%; cardiovascular, 15.7~64.73%) were observed, although, this does not appear to have a decisive effect on disease severity. Many anti-rheumatic treatments have been extensively evaluated for their efficacy of treating COVID-19 in RADs patients, with TNF-α inhibitors and IL-6 receptor antagonist receiving more positive reviews. However, there is no conclusive information for most of the therapeutic regimens due to the lack of high-level evidence. Inflammatory markers or neutrophil-lymphocyte-ratio may be applied as indicators for clinical prognosis or therapeutic regimens adjustment. Thus, more research is still needed to address the prevalence, treatment, and clinical monitoring of RADs patients in COVID-19 pandemic.

show abstract

“…The immune system alterations that emerge in the course of various rheumatic diseases (RD) create a potential that cannot be ignored for the occurrence of intense viremia and the severe new type of coronavirus disease 2019 (COVID-19) [ 1 ]. High disease activity, comorbid disorders secondary to RD, and medications are other potential risk factors for COVID-19 in this group of patients [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

YouTube as a source of information on COVID-19 vaccination in rheumatic diseases

Koçyiğit

Akyol

2021

Rheumatol Int

View full text Add to dashboard Cite

As the most well-known and popular video-sharing platform around the world, YouTube is an influential tool for the dissemination of health-related information. In addition, considering the increase in obtaining information from internet-based sources in pandemic conditions, YouTube has become more important in the presentation of information related to COVID-19. Therefore, the aim of this study was to evaluate videos related to COVID-19 vaccination in rheumatic diseases (RD) on YouTube. In this descriptive study, 334 video URLs listed with six search terms were recorded (26 July 2021). Three quality groups (high, intermediate, and low) were created based on the Global Quality Scores (GQS). Video sources were identified and various video parameters were compared between the quality groups. Following the implementation of the exclusion criteria, 56 videos remained for further analysis; of which 37 (66.07%) were evaluated as high quality, 12 (21.42%) as intermediate quality, and 7 (12.51%) as low quality. No significant difference was determined between the quality groups in per day values of views, likes, dislikes, and comments. The sources of high-quality videos were pharmaceutical company ( n = 1; 100%), pharmacist ( n = 1; 100%), society-organization ( n = 17; 85%), and academic ( n = 3; 75%). Although two-thirds of the videos were high quality, it should be kept in mind that intermediate and low-quality videos are also available. Users should not assume the quality of the videos based on the number of views, likes, dislikes, and comments, but should focus more on video sources.

show abstract

COVID-19, rheumatic diseases and immune dysregulation—a perspective

Cited by 14 publications

References 100 publications

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review

YouTube as a source of information on COVID-19 vaccination in rheumatic diseases

Contact Info

Product

Resources

About